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Approximately 6 000 new cervical cancer cases are 
diagnosed annually in South Africa (SA). Accurate 
contemporary data on cervical cancer incidence have 
not been available since the 1999 Cancer Registry 
was published.[1] It is assumed that many cases are 
still undiagnosed and that more than half of diagnosed patients 
will die per year. The World Health Organization estimates the age-
standardised incidence rate for SA to be 26.6 per 100  000 women.
[2] The current prevalence of pre-invasive cervical disease in SA is 
largely unknown. Data from published SA studies suggest important 
regional differences and an increase in the prevalence of cytological 
abnormalities when compared with historical data.[3-5] Because of the 
low sensitivity of cytology, it can be assumed that the true prevalence 
of pre-invasive disease is underestimated by all available data. A single 
test of cervical cytology, even if optimal, will probably identify fewer 
than half of all existing pre-invasive cervical disease when measured 
against the greater yield obtained at colposcopy and directed biopsy.[6]
The identification of high-risk human papillomavirus (hrHPV) 
types (the cause of cervical cancer) offers the prospect of improving 
cervical screening programmes through the introduction of hrHPV-
based screening tests. Studies from developed countries provide 
convincing evidence that hrHPV DNA-based screening algorithms 
are cost-effective and clinically sensitive for the detection of 
precancerous lesions[7-9] and invasive cervical cancer[10] compared with 
cytology-based screening in women older than 30. Recently, this 
finding has also been confirmed in India, a developing country with 
a low human immunodeficiency virus (HIV) prevalence.[11] Over the 
last 20 years, the widespread HIV epidemic has increased the overall 
burden of HPV infection in sub-Saharan Africa.[12] Accurate current 
knowledge of the genital hrHPV prevalence in developing countries 
is essential for cost analysis and planning for regionally tailored 
national prevention and screening programmes. The purpose of this 
study was to describe the type- and age-specific prevalence of HPV 
infection and cytological abnormalities among women in Gauteng.
Method
Study population
Women attending public sector primary healthcare clinics for routine 
gynaecological and non-gynaecological primary healthcare-related 
reasons were invited to participate in a cervical cancer screening 
study. The study was conducted at 5 clinics in the Tshwane District 
of Gauteng province that were known to have no cervical cancer 
screening services in place. The sampling period started in July 2008 
and terminated in June 2011. All women with a history of previous or 
current sexual activity who were able to provide written consent were 
included in the study. Ethics approval was obtained from the Faculty 
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of Health Sciences Research Ethics Committee, University of Pretoria 
Ethics Board (Protocol no. 210/2008).
Specimen collection and testing
All participants were screened with conventional cytology (Pap 
smear) as per national protocol. Cytopathology reports were based 
on the Bethesda system.[13] Specimens for HPV genotyping were either 
healthcare worker-collected dry cervical swabs (N=951) or patient-
collected tampon specimens (N=573). Tampons were placed in a 
phosphate buffered saline and 10% methanol solution directly after 
collection. DNA extraction was performed in batches on washed cell 
pellets of the tampon specimens or directly on the dry swab specimens 
using the DNA Isolation Kit (Roche Molecular Systems, Branchburg, 
NJ) on the MagNA Pure automated extraction system. HPV genotyping 
was done using the HPV linear array (LA) genotyping kit (Roche 
Molecular Systems, Branchburg, NJ). The pool of primers is designed 
to amplify HPV DNA from 15 high-risk genotypes (16, 18, 31, 33, 35, 
39, 45, 51, 52, 56, 58, 59, 68, 73 and 82), 3 probable high-risk genotypes 
(26, 53 and 66) and 19 low/undetermined-risk types (6, 11, 40, 42, 54, 
55, 61, 62, 64, 67, 69, 70, 71, 72, 81, 83, 84, IS39 and CP6108). The 
β-globin gene was amplified concurrently to assess cellular adequacy, 
extraction and amplification for each individually processed specimen. 
Strict procedures were followed to avoid contamination, with negative 
and positive controls included in each run.
Data and statistical analysis
HPV genotypes were classified based on the results of Muñoz et al., 
which regarded 15 types as hrHPV (16, 18, 31, 33, 35, 39, 45, 51, 
52, 56, 58, 59, 68, 73 and 82), among which 3 types (26, 53 and 66) 
are recognised as probable hrHPV for cervical cancer.[14] The 8 most 
common hrHPV types found in invasive cervical cancer (16, 18, 31, 
33, 35, 45, 52, 58) as described by De Sanjose were classified as the 
‘top 8’.[15] The overall total HPV, type-specific HPV, total hrHPV, ‘top 
8’ hrHPV, and type 16 and/or 18, prevalence and cytology result 
(normal, atypical squamous cells of undetermined significance 
(ASCUS)), low-grade squamous intraepithelial lesion (LSIL), high-
grade squamous intraepithelial lesion (HSIL) and cervical carcinoma 
and their 95% confidence intervals (CIs) were determined for 
the total study population and per age group. Data were analysed 
considering study sites as strata associated with the collection 
method and using sampling weights to account for study design. 
Since sampling took place without replacement, a finite population 
correction was also applied to the variance estimator to yield study-
design-based CIs for the prevalence of interest. All statistical analyses 
were performed using Stata software, release 11.0 (StataCorp LP, 
College Station, Texas, USA).
Results
Characteristics of the study population
Of the 1 524 women who participated in the study, complete age 
data and cytology results were available for 1 445 and 1 472 women 
respectively. Data excluded from the analysis were the result of no 
or incomplete specimens received (n=11), no age data available 
(n=41), cytology not adequate for analysis (n=11) and/or invalid 
HPV results (n=20). Cytology (33.0%, n=477) and HPV genotyping 
(4.6%, n=66) indicated as possibly inadequate because of lack of 
endocervical cells or low β-globin gene amplification were included 
in the analysis. The median age of participating women was 39 years 
(range 16 - 83).
HPV DNA prevalence and age distribution
HPV DNA was detected in 74.6% (n=1 078) of women, with 
the highest prevalence of 85% in women younger than 25 years. 
Overall, hrHPV DNA was present in 54.3% (n=784) of subjects. The 
prevalence also peaked in women younger than 25 years and then 
slightly decreased with age (Table 1 and Figs 1 and 2).
Multiple infections
Among women with hrHPV infection (n=784), 52.7% had infection 
with more than one type. Infection with more than one hrHPV 
type was more common in women younger than 40 years and again 
showed a rise in women older than 55 years (Fig. 3).
Cervical cytology
Abnormal cytology was found in 17.3% (n=255) of samples. ASCUS 
was reported in 4.7% (n=69), LSIL in 3.0% (n=44) and HSIL in 9.1% 
(n=134) of patients. Eight patients (0.5%) had cytology suggestive 
of squamous carcinoma (Table 2, Fig. 2). Abnormal cytology was 
highest in the 30 - 34-year-old age group (25.5%) with a decline after 
age 44, matching the gradient of the hrHPV infection curve. HSIL 
lesions, or worse, were detected in 9.6% of women overall. These 
lesions were detected from a young age, with 8.8% prevalence in 
women <25 years of age, similar to the 9.5% prevalence in the 25 - 
29-year age group. The prevalence peaked in the age group 30 - 34 
years (16.2%), with the second-highest prevalence among women 
aged 40 - 44 (13.6%).
Table 1. HPV age-specific prevalence percentage (95% CI) per HPV type or ‘pooled’ types (see text)
Age group N HPV+ hrHPV+ HPV 16+ HPV 18+ HPV 16/18+ HPV ‘top 8’
<25 100 85.0 (75.5 - 91.4) 66.0 (57.6 - 74.4) 17.0 (10.6 - 23.5) 8.0 (3.4 - 12.6) 24.0 (16.6 - 31.4) 49.0 (40.3 - 57.7)
25 - 29 186 79.6 (73.1 - 85.1) 62.9 (56.7 - 69.1) 15.1 (10.5 - 19.6) 9.7 (5.9 - 13.4) 22.0 (16.8 - 27.3) 52.2 (45.7 - 58.6)
30 - 34 233 79.4 (73.6 - 84.4) 61.8 (56.5 - 67.1) 18.0 (13.7 - 22.4) 9.9 (6.5 - 13.2) 24.5 (19.6 - 29.3) 51.1 (45.5 - 56.6)
35 - 39 215 72.6 (66.1 - 78.4) 59.5 (53.9 - 65.2) 14.0 (9.9 - 18.1) 8.4 (5.2 - 11.6) 21.4 (16.6 - 26.2) 50.7 (45.0 - 56.4)
40 - 44 206 77.2 (70.8 - 82.7) 55.8 (49.9 - 61.8) 14.1 (9.9 - 18.2) 6.3 (3.4 - 9.2) 18.5 (13.9 - 23.0) 42.7 (36.8 - 48.6)
45 - 49 180 67.8 (60.4 - 74.5) 44.4 (38.0 - 50.9) 10.6 (6.6 - 14.5) 6.7 (3.4 - 9.9) 15.6 (10.9 - 20.2) 34.4 (28.3 - 40.6)
50 - 54 146 64.4 (56.0 - 72.1) 40.4 (33.4 - 47.5) 10.3 (6.0 - 14.6) 5.5 (2.3 - 8.6) 13.7 (8.9 - 18.5) 27.4 (21.0 - 33.8)
≥55 179 72.1 (64.9 - 78.5) 41.9 (35.7 - 48.1) 8.4 (4.8 - 12.0) 8.4 (4.8 - 12.0) 15.6 (10.9 - 20.3) 36.3 (30.3 - 42.4)
Total 1 445 74.6 (69.5 - 79.1) 54.3 (53.0 - 56.5) 13.5 (12.0 - 15.0) 8.0 (6.7 - 9.2) 19.5 (17.7 - 21.3) 43.5 (41.3 - 45.8)
 hrHPV = high-risk human papillomavirus.
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Discussion
HPV DNA prevalence and age distribution
The prevalence of cervical HPV infection, overall and by age, varies 
by continent, country, region and population subgroup. Reported 
prevalence is also affected by sampling method and the sensitivity of the 
chosen assay. The highest prevalence is reported in studies conducted 
in populations in sub-Saharan Africa and in HIV-positive cohorts. A 
study among women from urban and rural Tanzania demonstrated 
an hrHPV prevalence of 20.1% using the hybrid capture 2 (HC2) test 
(Qiagen).[16] Another population-based study from rural Nigeria used 
a modified MY09-MY11 polymerase chain reaction (PCR)-based 
method and found an hrHPV prevalence of 14.7%.[17] A smaller study 
(N=153) from our region reported an overall HPV prevalence of 58% 
using the LA.[18] Snijders et al. recommend that to accurately study 
HPV epidemiology, impact of HPV infection and monitor the efficacy 
of HPV vaccination programmes, the test with the highest analytical 
sensitivity possible must be used.[19] This shift toward highly sensitive 
PCR assays has affected findings in recent epidemiological studies, 
showing that HPV infections are more widespread than had previously 
been recognised.[20] In the current study, the highly analytically sensitive 
HPV LA was used. The overall HPV and hrHPV prevalence of 74.6% 
and 54.3% represents the highest prevalence ever reported in a sample 
of the general population.
HPV prevalence is described as peaking in women <25 years old, with 
a rapid fall in their 30s and 40s.[21] Inconsistent trends in HPV prevalence 
Table 2. Cytological abnormality age-specific prevalence percentage (95% CI)
Age group N Cytology abnormal ASCUS LSIL HSIL Cervical carcinoma
<25 102 16.7 (10.0 - 25.3) 2.0 (0.2 - 6.9) 5.9 (2.2 - 12.4) 8.8 (4.1 - 16.1) 0.0 (0.0 - 0.0)
25 - 29 189 19.6 (14.2 - 26.0) 5.8 (2.9 - 10.2) 4.2 (1.8 - 8.2) 9.0 (5.3 - 14.0) 0.5 (0.0 - 2.9)
30 - 34 235 25.5 (20.1 - 31.6) 5.1 (2.7 - 8.8) 4.3 (2.1 - 7.7) 15.7 (11.3 - 21.0) 0.4 (0.0 - 2.4)
35 - 39 220 19.1 (14.1 - 24.9) 5.0 (2.5 - 8.8) 2.3 (0.1 - 5.2) 11.8 (7.9 - 16.8) 0.0 (0.0 - 1.7)
40 - 44 214 22.0 (16.6 - 28.1) 5.6 (2.9 - 9.6) 2.8 (1.0 - 6.0) 12.6 (8.5 - 17.8) 0.9 (0.1 - 3.4)
45 - 49 182 10.4 (6.4 - 15.8) 5.0 (2.3 - 9.2) 1.7 (0.3 - 4.7) 1.7 (0.3 - 4.7) 2.2 (0.6 - 5.5)
50 - 54 149 11.4 (6.8 - 17.6) 2.7 (0.7 - 6.7) 2.7 (0.7 - 6.7) 6.0 (2.8 - 11.2) 0.0 (0.0 - 2.5)
≥55 181 8.8 (5.1 - 14.0) 4.4 (1.9 - 8.5) 1.1 (0.1 - 3.9) 3.3 (1.2 - 7.1) 0.0 (0.0 - 2.0)
Total 1 472 17.3 (12.6 - 23.4) 4.7 (3.9 - 5.7) 3.0 (2.0 - 4.4) 9.1 (5.6 - 14.5) 0.5 (0.2 - 1.7)
ASCUS = atypical squamous cells of undetermined significance; LSIL = low-grade squamous intraepithelial lesion; HSIL = high-grade squamous intraepithelial lesion.
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Fig. 1. Cumulative age-specific prevalence of any HPV DNA divided into 
HPV 16 and/or 18 positive, hrHPV other than type 16 or 18 positive, and 
only lrHPV positive.
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Fig. 2. Age-specific prevalence of hrHPV,* ‘top 8’ cancer-causing hrHPV,† 
HPV type 16 and/or 18 positive, cytological abnormalities‡ and estimated 
background HIV prevalence.§
*HPV DNA positive for one or more of 15 oncogenic HPV types.
†The eight most common hrHPV types found in invasive cervical cancer (16, 18, 31, 33, 35, 45, 52, 58).[15] 
‡Classification by severity: atypical squamous cells of undetermined significance (ASCUS), low-grade 
squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), cervical 
squamous carcinoma (SqCa).
§Most recent population estimates.[27]
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(hrHPV) as a percentage of women with hrHPV infections.
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are noted in older women, with most studies reporting a decrease of 
HPV infection in older ages while others document an increase or 
second peak.[21,22] Elevated HPV prevalence across all age groups, with 
flat or plateau-like age curves, has been observed in the lowest-income 
areas of Asia and Nigeria along with high or very high incidence of 
cervical cancer and mortality. This finding has also been documented 
in communities with no or inadequate screening programmes[22,23] and 
among HIV-positive women living on different continents.[22]
The high HPV prevalence and plateau-like age curve observed in this 
cohort could reflect several factors. These include sexual behavioural 
patterns, the largely unscreened and therefore untreated status of the 
female population owing to the inadequate implementation of cervical 
cancer screening programmes,[24,25] as well as the high background HIV 
prevalence (Fig. 2) and associated immune compromise in SA women. 
From 2009 to 2011, it was estimated that 19.1 - 19.4% of SA women aged 
15 - 49 years were HIV positive.[26] The national HIV prevalence survey, 
published in 2008, found that HIV prevalence peaks in females aged 
25 - 29 years at 32.7%, and ranges from 21.1% in 20 - 24-year-olds, to 
29.1% in the 30 - 34 age group, 24.8% in the 35 - 39 group, 16.3% in the 
40 - 44 group, and 14.1% in the 45 - 49 group.[27] Subsequent antenatal 
survey trend data from 2007 to 2010 showed that HIV prevalence was 
increasing among women aged 30 and older,[28] with a shift of the peak 
HIV prevalence to the age category 30 - 34 years.[26] Several studies 
have demonstrated a significantly higher prevalence of cervical cancer, 
pre-cancerous lesions and HPV infection in HIV-infected women 
than among HIV-uninfected women.[12,16,29-31]  HIV-infected women also 
have a higher frequency of infection with multiple HPV types,[31,32] and 
persistence or reactivation of infections is more likely. [32,33] Increased and 
accelerated progression rates to cervical cancer also lead to a younger 
mean age at diagnosis of pre-invasive and invasive disease.[34]
It is crucial that HIV testing be promoted among women being 
screened for cervical cancer. Importantly, cervical cancer screening 
should become an integral part of the chronic care of HIV-positive 
women. It is known that the risk of both HPV infection and 
cervical intraepithelial neoplasia increases with increasing degrees of 
immunosuppression. In SA, the general uptake of HIV testing is low, 
with late initiation of highly active antiretroviral therapy (HAART) 
at an average CD4 count of 87 cells/µl. In 2010, only 56% of those 
eligible for HAART in SA were receiving it.[28]
Multiple infection rate
Co-infection with multiple HPV types can be seen as an independent 
indicator of risk.[20] The high prevalence of multiple HPV infections 
and very high count of types in single patients probably reflects the 
combination of using a highly sensitive PCR assay and several risk 
factors in this population. The latter include: a high frequency of 
unprotected intercourse with multiple sexual partners in a population 
with a high background prevalence of HPV infection; a relative state 
of immune compromise in a large subset of the population owing 
to advanced and sub-optimally treated HIV infection or nutritional 
status; and genetic differences in host susceptibility.[20, 35]
Cytology
Previous local data from 2006 showed an abnormal cytology rate 
of 7.3% in the Western Cape and 10% in Gauteng.[25] The higher 
abnormality rate of 17.3% detected in this study population is expected, 
when considering the high HPV infection rate. Traditionally, high-
grade lesions are typically diagnosed in women 25 - 35 years old, 
while invasive cancer is more commonly diagnosed after age 40 
years, typically 8 - 13 years after diagnosis of a high-grade lesion. Of 
particular concern is that HSILs were seen in more than 8% of women 
<25 years old.
Limitations
Full genotyping assays are not advocated as screening assays because 
of their very high analytical sensitivity and low clinical specificity, 
their high cost, and labour-intensive laboratory methodology. Studies 
among women with cytological abnormalities have shown HC2 to 
have lower HPV positivity compared with PCR assays such as the 
LA.[36,37] The observed high HPV prevalence can not, however, be 
attributed to the sensitivity of the assay alone, as reflected by the 
concurrent high prevalence of cytological abnormalities and the 
pattern of multiple and single HPV infections that appears to mirror 
the background HIV prevalence per age groups (Figs 2 and 3). In 
view of the well-known large regional and population differences in 
HPV epidemiology, the results of this study cannot be generalised to 
the whole region or to the country.
Implications for primary prevention
The high sensitivity of the LA assay is considered of significant value 
as an epidemiological tool for prevalence studies of HPV infections as 
well as for pre- and post-prophylactic vaccine intervention.[37] These 
data predict that prophylactic vaccination of females prior to their 
sexual debut in this and similar populations could potentially prevent 
a large proportion of cervical HPV infections attributed to HPV 16 and 
18. Catch-up vaccination will be less beneficial and cost-effective, as at 
least 20% of women <25 years old are already exposed to HPV 16 and/
or 18 (Fig. 2). HAART can effectively increase cell-mediated immunity 
among sexually active people, which will reduce the burden of HPV 
infection in the population. Patterns of sexual behaviour that influence 
the epidemiology of HPV infection are more difficult to change.
Implications for secondary prevention
If women in developing regions are screened, it is usually only once or 
twice in a lifetime. The South African National Department of Health 
has a target of 70% cervical cancer screening coverage with cytology 
repeated at 10-year intervals. In 2006, Denny reported that less than 
10% of the targeted female population were actually screened. In 
some provinces, the coverage was as low as 2%.[25] It is of utmost 
importance to maximise sensitivity when a long screening interval 
is used and coverage is poor.[36] These data predict that an effective 
screening programme with a highly sensitive hrHPV DNA assay, in 
this and similar populations, will place an enormous burden on the 
healthcare system owing to the increase in the number of women 
requiring triage, follow-up and, ultimately, treatment. These results 
show that more than half of women will need further healthcare 
intervention if an hrHPV test-and-treat policy were to be introduced 
in women >30 years old. Highly sensitive non-discriminatory HPV 
DNA tests are therefore unsuitable for primary screening without 
further triage in low-resource settings. The ideal screening test 
should balance sensitivity with high clinical specificity or positive 
predictive value for disease.
To achieve 70% coverage of the population in SA, over 5 million 
women >30 years old would need to be screened every 10 years.[25] 
HPV genotyping or pooled partial genotyping of the ‘highest risk’ 
or ‘higher risk’ cervical cancer-causing HPV types will increase 
specificity while maintaining the sensitivity of the initial round of 
screening. The ‘highest risk’ viruses can be defined as HPV 16 and/
or 18, while the most prevalent four, six or eight HPV types found in 
cervical cancer can be chosen as the ‘higher risk’ types for screening 
purposes. Depending on the choice, the trade-off between sensitivity 
and specificity can be made according to cost-effectiveness. With 
100% coverage, screening for the top four types should prevent an 
estimated 80% of cancerous lesions, while screening for the ‘highest 
risk’ types only can be projected to prevent <70% in this context.[38]
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Data from this study can assist in predicting the possible outcomes 
of different screening test choices in this context. The age-specific 
prevalence curve shows that approximately 1 in every 4 women aged 
25 - 35, or 1 in every 5 women aged 35 - 45, will need treatment if 
positivity for HPV 16 or 18 is used as a stratification and treatment 
criterion. These percentages are comparable to the prevalence of 
cytological abnormalities in the same age groups. Screening for the 
presence of the ‘top 8’ HPV types will identify approximately 50% of 
women between 25 and 40 years and approximately 40% of women 
aged >40 who are at higher risk (Figs 1 and 2).
Conclusion
This unscreened female population, having a high background 
prevalence of sub-optimally treated HIV, is typical of many 
populations in the developing world. HPV infection, co-infection 
with several hrHPV types and abnormalities on cytology were more 
prevalent than previously appreciated. The plateau-like curve seen 
among age groups <45 years is unique. All these phenomena probably 
reflect a combination of factors. Follow-up data are needed to clarify 
to what extent the high HPV prevalence in middle- and older-aged 
women is related to the persistence or reactivation of old infections, 
acquisition of new infections, or cohort effects.
The increased HPV prevalence determined in this sample of the SA 
population underscores the urgent need for improved cervical cancer 
screening and prevention programmes to prevent a marked increase in 
the incidence of cervical cancer in the next decade. These data provide 
an indication of the 40 - 50% of women who would require follow-
up if primary HPV screening were introduced. It also indicates the 
magnitude of possible benefit were prophylactic HPV vaccination to 
be introduced. Future evaluations of the performance of new clinically 
sensitive and specific HPV screening tests are required to design 
practical and realistic screening programmes for SA.
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